MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Business/Financial News / Boardroom shuffle puts NMT Medical at risk for de-listing

Boardroom shuffle puts NMT Medical at risk for de-listing

September 14, 2010 By MassDevice staff Leave a Comment

NMTI logo

The NASDAQ stock exchange shot another de-listing warning across NMT Medical Inc.’s (NSDQ:NMTI) bow, after an August boardroom shuffle left it without enough directors to man its audit committee.

The Boston-based company revealed the warning in a filing with the federal Securities & Exchange Commission.

The company’s troubles began June 17, when it reported that its flagship StarFlex device failed to meet the primary endppint of a clinical trial. The news sent NMTI’s stock price on a 79 percent dive that day; shares have averaged under 50 cents since then, a far cry from an all-time high of $24.56. Trying to regroup, NMT said it would "tightly manage expenses, preserve cash, evaluate financing alternatives and adjust our operating plan accordingly," as it waits for the final results of the Closure I trial to be completed in November, according to its second-quarter earnings release. In August, the company’s poor stock performance drew a first de-listing warning from the NASDAQ exchange. Later that month, former CEO Frank Martin and chairman James Mahoney stepped down, with COO Richard Davis taking the helm as chairman, president and CEO.

NMT has either until its next shareholders meeting or Aug. 25, 2011, to bolster its audit committee and regain the exchange’s good graces. The company hasn’t decided how it will respond to the warning, according to the filing, but Davis told MassDevice in an email that, “Currently it is the plan of the company to look to add a board member that will help it get back into compliance with the ‘financial expert’ aspect of the listing qualifications.”

Filed Under: Business/Financial News, Cardiac Implants, News Well Tagged With: NMT Medical Inc.

In case you missed it

  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • Orthofix names new president of global spine business
  • J&J Vision launches Tecnis Toric II intraocular lens in U.S.
  • NOUS Imaging picks up $6.6m for brain-imaging software
  • MicroVention issues safety notice for Azur endovascular embolization products
  • Study reveals long-term outcomes of Boston Scientific Watchman patients
  • 3M issues safety notice for Durapore surgical tape
  • FDA clearance positions Sight Diagnostics to deliver on two-drop blood testing promise
  • TransMedics touts first U.S. ‘reanimated’ heart transplants
  • Micro-Leads collects $10m for neuromod therapy
  • Viant to cease ethylene oxide sterilization at Michigan plant by year’s end
  • Venclose closes $27m Series C
  • CSA Medical wins CE Mark approval for RejuvenAir System
  • N2 Biomedical appoints new chief financial officer
  • Senate committee favors Hahn for FDA chief
  • IntraVu raises $11.7m for tiny imaging system
  • Mobile ECG management? There’s a new app in the works

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS